The pharmacotherapeutic management of gastroesophageal reflux disease (GERD)

References

• Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012;143(5):1179–1187. e3.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871–880.
   PubMed Web of Science ®Google Scholar
• Richter JE, Rubenstein JH. Presentation and epidemiology of gastroesophageal reflux disease. Gastroenterology. 2018;154(2):267–276.
   PubMed Web of Science ®Google Scholar
• Eusebi LH, Ratnakumaran R, Yuan Y, et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67(3):430–440.
   PubMed Web of Science ®Google Scholar
• Yadlapati R, Dakhoul L, Pandolfino JE, et al. The quality of care for gastroesophageal reflux disease. Dig Dis Sci. 2017;62(3):569–576.
   PubMed Web of Science ®Google Scholar
• Vakil N, van Zanten SV, Kahrilas P, et al. The montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–1920. quiz 43.
   PubMed Web of Science ®Google Scholar
• Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45(2):172–180.
   PubMed Web of Science ®Google Scholar
• Savarino E, de Bortoli N, De Cassan C, et al. The natural history of gastro-esophageal reflux disease: a comprehensive review. Dis Esophagus. 2017;30(2):1–9.
   PubMed Web of Science ®Google Scholar
• Mermelstein J, Chait Mermelstein A, Chait MM. Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions. Clin Exp Gastroenterol. 2018;11:119–134.
   PubMed Web of Science ®Google Scholar
• Bardou M, Fortinsky KJ, Chapelle N, et al. An update on the latest chemical therapies for reflux esophagitis in children. Expert Opin Pharmacother. 2019;20(2):231–239.
   PubMed Web of Science ®Google Scholar
• Cremonini F, Ziogas DC, Chang HY, et al. Meta-analysis: the effects of placebo treatment on gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2010;32(1):29–42.
   PubMed Web of Science ®Google Scholar
• Gyawali CP, Fass R. Management of gastroesophageal reflux disease. Gastroenterology. 2018;154(2):302–318.
   PubMed Web of Science ®Google Scholar
• Decktor DL, Robinson M, Maton PN, et al. Effects of aluminum/magnesium hydroxide and calcium carbonate on esophageal and gastric pH in subjects with heartburn. Am J Ther. 1995;2(8):546–552.
   PubMedGoogle Scholar
• Malmud LS, Charkes ND, Littlefield J, et al. The mode of action alginic acid compound in the reduction of gastroesophageal reflux. J Nucl Med. 1979;20(10):1023–1028.
   PubMed Web of Science ®Google Scholar
• McRorie JW, Kirby JA, Miner PB. Histamine2-receptor antagonists: rapid development of tachyphylaxis with repeat dosing. World J Gastrointest Pharmacol Ther. 2014;5(2):57–62.
   PubMedGoogle Scholar
• Moayyedi P, Leontiadis GI. The risks of PPI therapy. Nat Rev Gastroenterol Hepatol. 2012;9(3):132–139.
   PubMed Web of Science ®Google Scholar
• Carter D, Dickman R. Practice styles, knowledge and attitudes of general practitioners and gastroenterology specialists who treat gastroesophageal reflux disease. Medicine (Baltimore). 2018;97(52):e13781.
   PubMed Web of Science ®Google Scholar
• Oshima T, Miwa H. Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil. 2018;24(3):334–344.
   PubMed Web of Science ®Google Scholar
• Scarpignato C, Hunt RH. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Curr Opin Gastroenterol. 2019;35(4):344–355.
   PubMed Web of Science ®Google Scholar
• Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41(7):636–648.
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol. 2015;6(6):e94.
   PubMedGoogle Scholar
• Otake K, Sakurai Y, Nishida H, et al. Characteristics of the novel potassium-competitive acid blocker Vonoprazan fumarate (TAK-438). Adv Ther. 2016;33(7):1140–1157.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Zhang S, Dai N, et al. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut. 2020;69(2):224–230.
   PubMed Web of Science ®Google Scholar
• Dent J, Kahrilas PJ, Hatlebakk J, et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol. 2008;103(1):20–26.
   PubMed Web of Science ®Google Scholar
• Kojima Y, Takeuchi T, Sanomura M, et al. Does the novel potassium-competitive acid blocker vonoprazan cause more hypergastrinemia than conventional proton pump inhibitors? A multicenter prospective cross-sectional study. Digestion. 2018;97(1):70–75.
   PubMed Web of Science ®Google Scholar
• Schneider JH, Kuper MA, Konigsrainer A, et al. Transient lower esophageal sphincter relaxation and esophageal motor response. J Surg Res. 2010;159(2):714–719.
   PubMed Web of Science ®Google Scholar
• Spechler SJ, Hunter JG, Jones KM, et al. Randomized trial of medical versus surgical treatment for refractory heartburn. N Engl J Med. 2019;381(16):1513–1523.
   PubMed Web of Science ®Google Scholar
• Dong R, Xu X, Yu L, et al. Randomised clinical trial: gabapentin vs baclofen in the treatment of suspected refractory gastro-oesophageal reflux-induced chronic cough. Aliment Pharmacol Ther. 2019;49(6):714–722.
   PubMed Web of Science ®Google Scholar
• Cossentino MJ, Mann K, Armbruster SP, et al. Randomised clinical trial: the effect of baclofen in patients with gastro-oesophageal reflux–a randomised prospective study. Aliment Pharmacol Ther. 2012;35(9):1036–1044.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang LN. Baclofen for alcohol withdrawal. Cochrane Database Syst Rev. 2019 Nov 6;2019(11):CD008502.
   Google Scholar
• Vakil NB, Huff FJ, Bian A, et al. Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol. 2011;106(8):1427–1438.
   PubMed Web of Science ®Google Scholar
• Shaheen NJ, Denison H, Bjorck K, et al. Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial. Gut. 2013;62(9):1248–1255.
   PubMed Web of Science ®Google Scholar
• Sigterman KE, van Pinxteren B, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;CD002095.
   PubMed Web of Science ®Google Scholar
• Hunt R, Armstrong D, Katelaris P, et al. World gastroenterology organisation global guidelines: GERD global perspective on gastroesophageal reflux disease. J Clin Gastroenterol. 2017;51(6):467–478.
   PubMed Web of Science ®Google Scholar
• Tran T, Lowry AM, El-Serag HB. Meta-analysis: the efficacy of over-the-counter gastro-oesophageal reflux disease therapies. Aliment Pharmacol Ther. 2007;25(2):143–153.
   PubMed Web of Science ®Google Scholar
• Thomas E, Wade A, Crawford G, et al. Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2014;39(6):595–602.
   PubMed Web of Science ®Google Scholar
• Wilkinson J, Wade A, Thomas SJ, et al. Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate-antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2019;31(1):86–93.
   PubMed Web of Science ®Google Scholar
• Leiman DA, Riff BP, Morgan S, et al. Alginate therapy is effective treatment for gastroesophageal reflux disease symptoms: a systematic review and meta-analysis. Dis Esophagus. 2017;30(2):1–8.
   Web of Science ®Google Scholar
• Bor S, Kalkan IH, Celebi A, et al. Alginates: from the ocean to gastroesophageal reflux disease treatment. Turk J Gastroenterol. 2019;30(Suppl2):109–136.
   PubMedGoogle Scholar
• Chiu CT, Hsu CM, Wang CC, et al. Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease. Aliment Pharmacol Ther. 2013;38(9):1054–1064.
   PubMed Web of Science ®Google Scholar
• Pouchain D, Bigard MA, Liard F, et al. Gaviscon(R) vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial. BMC Gastroenterol. 2012;12(1):18.
   PubMedGoogle Scholar
• Armstrong D, Pare P, Pericak D, et al. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol. 2001;96(10):2849–2857.
   PubMed Web of Science ®Google Scholar
• Weijenborg PW, Cremonini F, Smout AJ, et al. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil. 2012;24(8):747–757. e350.
   PubMed Web of Science ®Google Scholar
• Armstrong D. Veldhuyzen van Zanten SJ, Barkun AN, et al. Heartburn-dominant, uninvestigated dyspepsia: a comparison of ‘PPI-start’ and ‘H2-RA-start’ management strategies in primary care–the CADET-HR study. Aliment Pharmacol Ther. 2005;21(10):1189–1202.
   PubMed Web of Science ®Google Scholar
• Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology. 2001;121(5):1095–1100.
   PubMed Web of Science ®Google Scholar
• Zhang H, Yang Z, Ni Z, et al. A meta-analysis and systematic review of the efficacy of twice daily PPIs versus once daily for treatment of gastroesophageal reflux disease. Gastroenterol Res Pract. 2017;2017:9865963.
   PubMed Web of Science ®Google Scholar
• Giudicessi JR, Ackerman MJ, Camilleri M. Cardiovascular safety of prokinetic agents: a focus on drug-induced arrhythmias. Neurogastroenterol Motil. 2018;30(6):e13302.
   PubMed Web of Science ®Google Scholar
• Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology. 2016;150(6):1380–1392.
   PubMed Web of Science ®Google Scholar
• Savarino E, Zentilin P, Tutuian R, et al. The role of nonacid reflux in NERD: lessons learned from impedance-pH monitoring in 150 patients off therapy. Am J Gastroenterol. 2008;103(11):2685–2693.
   PubMed Web of Science ®Google Scholar
• Geeraerts A, Van Houtte B, Clevers E, et al. Gastroesophageal reflux disease-functional dyspepsia overlap: do birds of a feather flock together? Am J Gastroenterol. 2020. DOI:10.14309/ajg.0000000000000619
   PubMed Web of Science ®Google Scholar
• Lim HC, Kim JH, Youn YH, et al. Effects of the addition of mosapride to gastroesophageal reflux disease patients on proton pump inhibitor: a prospective randomized, double-blind study. J Neurogastroenterol Motil. 2013;19(4):495–502.
   PubMed Web of Science ®Google Scholar
• Futagami S, Iwakiri K, Shindo T, et al. The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying. J Gastroenterol. 2010;45(4):413–421.
   PubMed Web of Science ®Google Scholar
• Liu Q, Feng CC, Wang EM, et al. Efficacy of mosapride plus proton pump inhibitors for treatment of gastroesophageal reflux disease: a systematic review. World J Gastroenterol. 2013;19(47):9111–9118.
   PubMed Web of Science ®Google Scholar
• Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther. 1997;11(4):765–773.
   PubMed Web of Science ®Google Scholar
• Fullard M, Kang JY, Neild P, et al. Systematic review: does gastro-oesophageal reflux disease progress? Aliment Pharmacol Ther. 2006;24(1):33–45.
   PubMed Web of Science ®Google Scholar
• Graham DY, Patterson DJ. Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitis. Dig Dis Sci. 1983;28(6):559–563.
   PubMed Web of Science ®Google Scholar
• Madan K, Ahuja V, Kashyap PC, et al. Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. Dis Esophagus. 2004;17(4):274–278.
   PubMed Web of Science ®Google Scholar
• Yamaji Y, Isomura Y, Yoshida S, et al. Randomized controlled trial comparing the efficacy of mosapride plus omeprazole combination therapy to omeprazole monotherapy in gastroesophageal reflux disease. J Dig Dis. 2014;15(9):469–476.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Liu J, Tan X, et al. Direct comparison of the efficacy and safety of vonoprazan versus proton-pump inhibitors for gastroesophageal reflux disease: a systematic review and meta-analysis. Dig Dis Sci. 2020. DOI:10.1007/s10620-020-06141-5.
   Web of Science ®Google Scholar
• Wang WH, Huang JQ, Zheng GF, et al. Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol. 2005;11(26):4067–4077.
   PubMed Web of Science ®Google Scholar
• Edwards SJ, Lind T, Lundell L, et al. Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis – a mixed treatment comparison of randomized controlled trials. Aliment Pharmacol Ther. 2009;30(6):547–556.
   PubMed Web of Science ®Google Scholar
• Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther. 2001;23(7):998–1017.
   PubMed Web of Science ®Google Scholar
• Hsu PI, Lu CL, Wu DC, et al. Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis. Clin Gastroenterol Hepatol. 2015;13(5):859–866. e1.
   PubMed Web of Science ®Google Scholar
• Miyazaki H, Igarashi A, Takeuchi T, et al. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: a systematic review. J Gastroenterol Hepatol. 2019;34(8):1316–1328.
   PubMed Web of Science ®Google Scholar
• Ashida K, Iwakiri K, Hiramatsu N, et al. Maintenance for healed erosive esophagitis: phase III comparison of vonoprazan with lansoprazole. World J Gastroenterol. 2018;24(14):1550–1561.
   PubMed Web of Science ®Google Scholar
• Habu Y, Maeda K, Kusuda T, et al. “Proton-pump inhibitor-first” strategy versus “step-up” strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan. J Gastroenterol. 2005;40(11):1029–1035.
   PubMed Web of Science ®Google Scholar
• Yokoya Y, Igarashi A, Uda A, et al. Cost-utility analysis of a ‘vonoprazan-first’ strategy versus ‘esomeprazole- or rabeprazole-first’ strategy in GERD. J Gastroenterol. 2019;54(12):1083–1095.
   PubMed Web of Science ®Google Scholar
• Habu Y. Vonoprazan versus lansoprazole for the initial treatment of reflux esophagitis: a cost-effectiveness analysis in Japan. Intern Med. 2019;58(17):2427–2433.
   PubMed Web of Science ®Google Scholar
• El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther. 2010;32(6):720–737.
   PubMed Web of Science ®Google Scholar
• Farre R, van Malenstein H, De Vos R, et al. Short exposure of oesophageal mucosa to bile acids, both in acidic and weakly acidic conditions, can impair mucosal integrity and provoke dilated intercellular spaces. Gut. 2008;57(10):1366–1374.
   PubMed Web of Science ®Google Scholar
• Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut. 2009;58(2):295–309.
   PubMed Web of Science ®Google Scholar
• Yadlapati R, DeLay K. Proton pump inhibitor-refractory gastroesophageal reflux disease. Med Clin North Am. 2019;103(1):15–27.
   PubMed Web of Science ®Google Scholar
• Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308–328. quiz 29.
   PubMed Web of Science ®Google Scholar
• Yadlapati R, Vaezi MF, Vela MF, et al. Management options for patients with GERD and persistent symptoms on proton pump inhibitors: recommendations from an expert panel. Am J Gastroenterol. 2018;113(7):980–986.
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American gastroenterological association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135(4):1383–1391. 91 e1–5.
   PubMed Web of Science ®Google Scholar
• Kinoshita Y, Hongo M, Japan TSG. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study. Am J Gastroenterol. 2012;107(4):522–530.
   PubMed Web of Science ®Google Scholar
• Kinoshita Y, Kato M, Fujishiro M, et al. Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study. J Gastroenterol. 2018;53(7):834–844.
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Shirai N, Nishino M, et al. Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype. Aliment Pharmacol Ther. 2012;36(7):627–634.
   PubMed Web of Science ®Google Scholar
• Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016;51(8):751–767.
   PubMed Web of Science ®Google Scholar
• Hillman L, Yadlapati R, Thuluvath AJ, et al. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease. Dis Esophagus. 2017;30(9):1–15.
   Web of Science ®Google Scholar
• Ichikawa H, Sugimoto M, Sugimoto K, et al. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. J Gastroenterol Hepatol. 2016;31(4):716–726.
   PubMed Web of Science ®Google Scholar
• Manabe N, Haruma K, Ito M, et al. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial. Dis Esophagus. 2012;25(5):373–380.
   PubMed Web of Science ®Google Scholar
• Reimer C, Lodrup AB, Smith G, et al. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor. Aliment Pharmacol Ther. 2016;43(8):899–909.
   PubMed Web of Science ®Google Scholar
• Coyle C, Crawford G, Wilkinson J, et al. Randomised clinical trial: addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms. Aliment Pharmacol Ther. 2017;45(12):1524–1533.
   PubMed Web of Science ®Google Scholar
• Fackler WK, Ours TM, Vaezi MF, et al. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002;122(3):625–632.
   PubMed Web of Science ®Google Scholar
• Wang Y, Pan T, Wang Q, et al. Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough. Cochrane Database Syst Rev. 2009;4:CD004275. Published 2009 Oct 7. DOI:10.1002/14651858.CD004275.pub3.
   PubMed Web of Science ®Google Scholar
• Rackoff A, Agrawal A, Hila A, et al. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus. 2005;18(6):370–373.
   PubMed Web of Science ®Google Scholar
• Mainie I, Tutuian R, Castell DO. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough. J Clin Gastroenterol. 2008;42(6):676–679.
   PubMed Web of Science ®Google Scholar
• Sirinawasatien A, Kantathavorn N. Efficacy of the four weeks treatment of omeprazole plus mosapride combination therapy compared with that of omeprazole monotherapy in patients with proton pump inhibitor-refractory gastroesophageal reflux disease: a randomized controlled trial. Clin Exp Gastroenterol. 2019;12:337–347.
   PubMed Web of Science ®Google Scholar
• Yamashita H, Okada A, Naora K, et al. Adding acotiamide to gastric acid inhibitors is effective for treating refractory symptoms in patients with non-erosive reflux disease. Dig Dis Sci. 2019;64(3):823–831.
   PubMed Web of Science ®Google Scholar
• Li S, Shi S, Chen F, et al. The effects of baclofen for the treatment of gastroesophageal reflux disease: a meta-analysis of randomized controlled trials. Gastroenterol Res Pract. 2014;2014:307805.
   PubMed Web of Science ®Google Scholar
• Hoshino S, Kawami N, Takenouchi N, et al. Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis. Digestion. 2017;95(2):156–161.
   PubMed Web of Science ®Google Scholar
• Okuyama M, Nakahara K, Iwakura N, et al. Factors associated with potassium-competitive acid blocker non-response in patients with proton pump inhibitor-refractory gastroesophageal reflux disease. Digestion. 2017;95(4):281–287.
   PubMed Web of Science ®Google Scholar
• Gotoh Y, Ishibashi E, Honda S, et al. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease. Medicine (Baltimore). 2020;99(11):e19520.
   PubMed Web of Science ®Google Scholar
• Abe Y, Koike T, Saito M, et al. The ameliorating effect of switching to vonoprazan: a novel potassium-competitive acid blocker in patients with proton pump inhibitor refractory non-erosive reflux disease. Digestion. 2020:1–9. DOI:10.1159/000506152.
   PubMed Web of Science ®Google Scholar
• Akiyama J, Hosaka H, Kuribayashi S, et al. Efficacy of vonoprazan, a novel potassium-competitive acid blocker, in patients with proton pump inhibitor-refractory acid reflux. Digestion. 2020;101(2):174–183.
   PubMed Web of Science ®Google Scholar
• Shibli F, Kitayama Y, Fass R. Novel therapies for gastroesophageal reflux disease: beyond proton pump inhibitors. Curr Gastroenterol Rep. 2020;22(4):16.
   PubMedGoogle Scholar
• Vaezi MF, Fass R, Vakil N, et al. IW-3718 reduces heartburn severity in patients with refractory gastroesophageal reflux disease in a randomized trial. Gastroenterology. 2020;158(8):2093–2103.
   PubMed Web of Science ®Google Scholar
• Numans ME, Lau J, de Wit NJ, et al. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med. 2004;140(7):518–527.
   PubMed Web of Science ®Google Scholar
• Lanas-Gimeno A, Hijos G, Lanas A. Proton pump inhibitors, adverse events and increased risk of mortality. Expert Opin Drug Saf. 2019;18(11):1043–1053.
   PubMed Web of Science ®Google Scholar
• Targownik L. Discontinuing long-term PPI therapy: why, with whom, and how? Am J Gastroenterol. 2018;113(4):519–528.
   PubMed Web of Science ®Google Scholar
• Kurlander JE, Rubenstein JH, Richardson CR, et al. Physicians’ perceptions of proton pump inhibitor risks and recommendations to discontinue: a national survey. Am J Gastroenterol. 2020;115(5):689–696.
   PubMed Web of Science ®Google Scholar
• Katz PO. Editorial: refractory GERD-good drug, wrong patients? Aliment Pharmacol Ther. 2017;46(2):203–204.
   PubMed Web of Science ®Google Scholar
• Coleman HG, Xie SH, Lagergren J. The epidemiology of esophageal adenocarcinoma. Gastroenterology. 2018;154(2):390–405.
   PubMed Web of Science ®Google Scholar
• Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med. 2006;166(9):965–971.
   PubMedGoogle Scholar
• Sandhu DS, Fass R. Current trends in the management of gastroesophageal reflux disease. Gut Liver. 2018;12(1):7–16.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Graham DY, Satia JA, et al. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol. 2005;100(6):1243–1250.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Ankerst DP, Chen Y, et al. Epidemiologic risk factors in a comparison of a Barrett esophagus registry (BarrettNET) and a case-control population in Germany. Cancer Prev Res (Phila). 2020;13(4):377–384.
   PubMed Web of Science ®Google Scholar
• Fan WJ, Hou YT, Sun XH, et al. Effect of high-fat, standard, and functional food meals on esophageal and gastric pH in patients with gastroesophageal reflux disease and healthy subjects. J Dig Dis. 2018;19(11):664–673.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Gilger M, Carter J, et al. GERD is a risk factor for GERD in adolescents and young adults. Am J Gastroenterol. 2004;99(5):806–812.
   PubMed Web of Science ®Google Scholar
• Mone I, Kraja B, Bregu A, et al. Adherence to a predominantly mediterranean diet decreases the risk of gastroesophageal reflux disease: a cross-sectional study in a South Eastern European population. Dis Esophagus. 2016;29(7):794–800.
   PubMed Web of Science ®Google Scholar